Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

305
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
305
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

240
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
240
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

297
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
297
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

559
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
559
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

230
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
230
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

152
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
152

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationship of motor mechanisms to gastroparesis symptoms: toward individualized treatment.

American journal of physiology. Gastrointestinal and liver physiology·2021
Same author

Liraglutide reduces attenuation coefficient as a measure of hepatic steatosis during 16 weeks' treatment in nondiabetic obese patients: A pilot trial.

JGH open : an open access journal of gastroenterology and hepatology·2021
Same author

Human Intestinal Barrier: Effects of Stressors, Diet, Prebiotics, and Probiotics.

Clinical and translational gastroenterology·2021
Same author

Every Breath Test You Take: Practical Advice on Breath Testing Used to Detect Small Intestinal Bacterial Overgrowth.

Digestive diseases and sciences·2021
Same author

International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function.

Pharmacological reviews·2020
Same author

Review article: Elobixibat: a novel treatment for chronic constipation.

Alimentary pharmacology & therapeutics·2020

Related Experiment Video

Updated: Jul 17, 2025

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans
14:25

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans

Published on: September 21, 2019

7.3K

Cannabinoids and the Gastrointestinal Tract.

Michael Camilleri1, Ting Zheng1

  • 1Clinical Enteric Neuroscience Translational and Epidemiological Research, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|September 7, 2023
PubMed
Summary

Cannabinoids, especially CB2 agonists, show promise for treating gastrointestinal issues like gastroparesis and inflammatory conditions. Further research is needed to confirm benefits and understand risks for broader clinical use.

Keywords:
CannabisGastroparesisInflammatory Bowel DiseasesNauseaPain DisordersVomiting

More Related Videos

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.6K
Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

275

Related Experiment Videos

Last Updated: Jul 17, 2025

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans
14:25

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans

Published on: September 21, 2019

7.3K
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.6K
Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

275

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Immunology

Background:

  • Endocannabinoid system functions in digestive organs are documented.
  • CB2 receptor mechanisms are key for immune and sensory functions.
  • Cannabis use is rising, influenced by social factors and co-use disorders.

Purpose of the Study:

  • To review cannabinoid mechanisms and therapeutic potential in gastrointestinal disorders.
  • To examine the role of CB2 agonists in conditions like IBD, gastroparesis, and IBS.
  • To assess the impact of cannabinoids on GI motility, pain, and inflammation.

Main Methods:

  • Review of existing literature on cannabinoid mechanisms and clinical trials.
  • Analysis of studies involving CB2 agonists like cannabidiol and olorinab.
  • Evaluation of cannabinoid effects on immune, sensory, and motor functions in the GI tract.

Main Results:

  • Cannabinoids can relieve symptoms in gastroparesis and nausea syndromes.
  • CB2 agonists show potential in reducing abdominal pain and disease activity in IBD.
  • Cannabidiol improved gastroparesis symptoms, but not functional dyspepsia pain.
  • Olorinab reduced pain in IBD and IBS-C.

Conclusions:

  • Cannabinoids, particularly CB2-targeting agents, offer potential for GI inflammatory, gastroparesis, and pain disorders.
  • Further clinical trials are necessary to validate efficacy and safety.
  • Understanding the risk-benefit profile is crucial for optimizing cannabinoid use in gastroenterology.